Truist raises Molina Healthcare price target to $250
Truist Securities analyst David Macdonald maintains a Hold rating on Molina Healthcare and raises the price target to $250 from $205, indicating a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Truist Securities analyst David Macdonald has maintained a Hold rating on Molina Healthcare and increased the stock's price target to $250 from the previous $205. The revised target signals a higher valuation expectation for the company's shares despite the neutral investment stance.
Rating and Target Details
The research note updates the financial outlook for Molina Healthcare without altering the Hold recommendation. The new price target of $250 represents a significant increase from the prior level of $205.
| Metric | Value |
|---|---|
| Rating | Hold |
| Previous Price Target | $205 |
| New Price Target | $250 |
The adjustment provides investors with a revised benchmark for the stock's potential performance, aligning with the analyst's latest assessment of the company's fundamentals and market position.
What specific fundamental improvements justify the $45 price target increase while maintaining a Hold rating?
Could the raised price target signal a potential future upgrade to a Buy rating if Molina meets certain performance milestones?
How might this valuation adjustment influence other analysts' ratings and price targets for Molina Healthcare?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
